PriceTargets.com logo

Actinium Pharmaceuticals - ATNM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.72
  • Forecasted Upside: 265.86%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.03 As of 04/24/2024 01:00 AM ET
▲ +0.07 (1.01%)

This chart shows the closing price for ATNM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Actinium Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNM

Analyst Price Target is $25.72
▲ +265.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Actinium Pharmaceuticals in the last 3 months. The average price target is $25.72, with a high forecast of $50.00 and a low forecast of $11.60. The average price target represents a 265.86% upside from the last price of $7.03.

This chart shows the closing price for ATNM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Actinium Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$21.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
3/19/2024Maxim GroupBoost TargetBuy ➝ Buy$20.00 ➝ $30.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
12/11/2023B. RileyLower TargetBuy ➝ Buy$20.00 ➝ $16.00
10/3/2023B. RileyReiterated RatingBuy ➝ Buy$20.00
9/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
9/6/2023HSBCInitiated CoverageBuy$11.60
8/15/2023HC WainwrightLower TargetBuy ➝ Buy$53.00 ➝ $50.00
4/20/2023HC WainwrightReiterated RatingBuy$53.00
4/4/2023Cantor FitzgeraldBoost Target$26.00 ➝ $27.00
2/21/2023HC WainwrightReiterated RatingBuy$53.00
2/21/2023William BlairDowngradeOutperform ➝ Market Perform
2/7/2023HC WainwrightReiterated RatingBuy$53.00
10/31/2022B. RileyBoost TargetBuy$16.00 ➝ $18.00
10/31/2022HC WainwrightBoost TargetBuy$45.00 ➝ $53.00
10/31/2022Maxim GroupBoost Target$25.00 ➝ $35.00
9/8/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00
8/25/2022B. RileyInitiated CoverageBuy$16.00
4/12/2022HC WainwrightReiterated RatingBuy$45.00
10/6/2021Maxim GroupReiterated RatingBuy$25.00
9/15/2021Alliance Global PartnersBoost TargetBuy$20.00 ➝ $25.00
8/3/2021HC WainwrightLower TargetBuy$57.00 ➝ $45.00
4/1/2021HC WainwrightLower TargetBuy$65.00 ➝ $57.00
3/10/2021HC WainwrightReiterated RatingBuy$65.00
12/31/2020William BlairReiterated RatingBuy
12/7/2020HC WainwrightReiterated RatingBuy$65.00
12/4/2020William BlairReiterated RatingBuy
11/5/2020Alliance Global PartnersInitiated CoverageBuy$25.00
8/21/2020Maxim GroupReiterated RatingBuy
6/4/2020HC WainwrightReiterated RatingBuy
6/4/2020HC WainwrightInitiated CoverageBuy$90.00
4/17/2020Maxim GroupInitiated CoverageBuy$45.00
12/11/2019Maxim GroupReiterated RatingBuy$45.00
10/25/2019Maxim GroupReiterated RatingBuy$45.00
8/8/2019William BlairReiterated RatingOutperform
8/8/2019William BlairInitiated CoverageOutperform
6/4/2019Maxim GroupSet TargetBuy$90.00
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 11 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/25/2024
  • 11 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 11 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Actinium Pharmaceuticals logo
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
Read More

Today's Range

Now: $7.03
Low: $6.88
High: $7.31

50 Day Range

MA: N/A

52 Week Range

Now: $7.03
Low: $4.00
High: $9.86

Volume

153,424 shs

Average Volume

324,604 shs

Market Capitalization

$206.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Actinium Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Actinium Pharmaceuticals in the last year: B. Riley, Cantor Fitzgerald, HC Wainwright, HSBC Holdings plc, Maxim Group, and StockNews.com.
View the latest analyst ratings for ATNM.

What is the current price target for Actinium Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Actinium Pharmaceuticals in the last year. Their average twelve-month price target is $25.72, suggesting a possible upside of 265.9%. HC Wainwright has the highest price target set, predicting ATNM will reach $50.00 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of $11.60 for Actinium Pharmaceuticals in the next year.
View the latest price targets for ATNM.

What is the current consensus analyst rating for Actinium Pharmaceuticals?

Actinium Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATNM will outperform the market and that investors should add to their positions of Actinium Pharmaceuticals.
View the latest ratings for ATNM.

What other companies compete with Actinium Pharmaceuticals?

Other companies that are similar to Actinium Pharmaceuticals include Design Therapeutics, Organigram, Galectin Therapeutics, Rigel Pharmaceuticals and Zevra Therapeutics. Learn More about companies similar to Actinium Pharmaceuticals.

How do I contact Actinium Pharmaceuticals' investor relations team?

Actinium Pharmaceuticals' physical mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company's listed phone number is (646) 677-3870 and its investor relations email address is [email protected]. The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com. Learn More about contacing Actinium Pharmaceuticals investor relations.